+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Inhalation Anesthesia Market by Product, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • PDF Icon

    Report

  • 165 Pages
  • March 2020
  • Region: Global
  • Allied Market Research
  • ID: 5031462
The global inhalation anesthesia market was valued at $1,137 million in 2018 and is expected to reach $1,549 million by 2026, registering a CAGR of 4.2% from 2019 to 2026. Inhalation anesthetics are primarily used during surgical procedures to control pain, blood pressure, blood flow, and heart rate & rhythm of a patient. Further, inhalational anesthesia is primarily used for induction of general anesthesia and sedation purposes. The most widely used inhalational anesthetics are sevoflurane, desflurane, and nitrous oxide. Inhalational anesthetics usually result in respiratory depression, reduction in arterial blood pressure and cerebral metabolic demand, and a rise in cerebral blood flow. The most common side effect of inhalation anesthesia is nausea.



Significant rise in the number of emergency incidences and road accidents; surge in The prevalence of various disorders such as cancer, respiratory diseases, and gastrointestinal disorders; upsurge in number of surgical procedures; and an increased use of these in various disease diagnosis drive the inhalation anesthesia market growth. In addition, factors such as innovations in these devices and governmental support regarding the use of inhalation anesthetics further fuel the market growth. However, risks associated with certain therapeutic and diagnostic devices for neonates and low adoption rate of new technologies, owing to reluctance from physicians for treatment, restrain the growth of the respiratory care devices market. In addition, environmental concerns regarding vigorous usage of inhalation anesthesia is anticipated to hamper the market growth. Moreover, significant rise in elderly population and an increase in healthcare expenditures in developing economies are anticipated to provide lucrative growth opportunities for the market.

The market is segmented on the basis of product, application, end user, and region. By product it is segmented into sevoflurane, desflurane, isoflurane, and nitrous oxide. On the basis of application, it is bifurcated into induction and maintenance. By end user it is classified into hospitals and ambulatory surgical centers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Product
  • Sevoflurane
  • Desflurane
  • Isoflurane
  • Nitrous Oxide

By Application
  • Induction
  • Maintenance

By End User
  • Hospitals
  • Ambulatory Surgical Centers

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • AbbVie Inc.
  • Baxter International Inc.
  • Fresenius SE & Co.
  • Halocarbon Products Corporation
  • Hikma Pharmaceuticals PLC
  • Jiangsu Hengrui Medicine Co., Ltd
  • Lunan Pharmaceutical Group Co. Ltd
  • Novartis AG
  • Piramal Enterprises Ltd
  • Troikaa Pharmaceuticals Ltd

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of buyers
3.3.2. Low bargaining power of suppliers
3.3.3. Moderate threat of substitutes
3.3.4. Low threat of new entrants
3.3.5. Moderate competitive rivalry
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in number of surgeries
3.5.1.2. Surge in severe road accidents
3.5.2. Restraint
3.5.2.1. Stringent regulatory scenario
3.5.3. Opportunity
3.5.3.1. Growth opportunities in emerging economies
CHAPTER 4: INHALATION ANESTHESIA MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Sevoflurane
4.2.2. Key market trends and opportunities
4.2.3. Market size and forecast
4.2.4. Market share analysis, by country
4.3. Desflurane
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.3.3. Market share analysis, by country
4.4. Isoflurane
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market share analysis, by country
4.5. Nitrous Oxide
4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast
4.5.3. Market share analysis, by country
CHAPTER 5: INHALATION ANESTHESIA MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Induction
5.2.1. Market size and forecast
5.2.2. Market share analysis, by country
5.3. Maintenance
5.3.1. Market size and forecast
5.3.2. Market share analysis, by country
CHAPTER 6: INHALATION ANESTHESIA MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Market size and forecast
6.2.2. Market share analysis, by country
6.3. Ambulatory service centers
6.3.1. Market size and forecast
6.3.2. Market share analysis, by country
CHAPTER 7: INHALATION ANESTHESIA MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by country
7.2.3. North America market size and forecast, by product
7.2.4. North America Market size and forecast, by application
7.2.5. North America market size and forecast, by end user
7.2.5.1. U. S. market size and forecast, by product
7.2.5.2. U. S. market size and forecast, by application
7.2.5.3. U. S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by product
7.2.5.5. Canada market size and forecast, by application
7.2.5.6. Canada market size and forecast, by end user
7.2.5.8. Mexico market size and forecast, by product
7.2.5.9. Mexico market size and forecast, by application
7.2.5.10. Mexico market size and forecast, by end user
7.3. Europe
7.3.1. Key growth factors and opportunities
7.3.2. Market size and forecast, by country
7.3.3. Europe market size and forecast, by product
7.3.4. Europe Market size and forecast, by application
7.3.5. Europe market size and forecast, by end user
7.3.5.1. Germany market size and forecast, by product
7.3.5.2. Germany market size and forecast, by application
7.3.5.3. Germany market size and forecast, by end user
7.3.5.4. France market size and forecast, by product
7.3.5.5. France market size and forecast, by application
7.3.5.6. France market size and forecast, by end user
7.3.5.7. UK market size and forecast, by product
7.3.5.8. UK market size and forecast, by application
7.3.5.9. UK market size and forecast, by end user
7.3.5.10. Italy market size and forecast, by product
7.3.5.11. Italy market size and forecast, by application
7.3.5.12. Italy market size and forecast, by end user
7.3.5.13. Spain market size and forecast, by product
7.3.5.14. Spain market size and forecast, by application
7.3.5.15. Spain market size and forecast, by end user
7.3.5.17. Rest of Europe market size and forecast, by product
7.3.5.18. Rest of Europe market size and forecast, by application
7.3.5.19. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key growth factors and opportunities.
7.4.2. Asia-Pacific market size and forecast, by country
7.4.3. Asia-Pacific market size and forecast, by product
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by end user
7.4.6.1. Japan market size and forecast, by product
7.4.6.2. Japan market size and forecast, by application
7.4.6.3. Japan market size and forecast, by end user
7.4.6.4. China market size and forecast, by product
7.4.6.5. China market size and forecast, by application
7.4.6.6. China market size and forecast, by end user
7.4.6.8. India market size and forecast, by product
7.4.6.9. India market size and forecast, by application
7.4.6.10. India market size and forecast, by end user
7.4.6.11. Australia market size and forecast by product
7.4.6.12. Australia market size and forecast, by application
7.4.6.13. Australia market size and forecast, by end user
7.4.6.14. Rest of Asia-Pacific market size and forecast by product
7.4.6.15. Rest of Asia-Pacific market size and forecast, by application
7.4.6.16. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key growth factors and opportunities
7.5.2. LAMEA market size and forecast, by country
7.5.3. LAMEA market size and forecast, by product
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by end user
7.5.5.1. Brazil market size and forecast, by product
7.5.5.2. Brazil market size and forecast, by application
7.5.5.3. Brazil market size and forecast, by end user
7.5.5.4. Saudi Arabia market size and forecast, by product
7.5.5.5. Saudi Arabia market size and forecast, by application
7.5.5.6. Saudi Arabia market size and forecast, by end user
7.5.5.7. South Africa market size and forecast, by product
7.5.5.8. South Africa market size and forecast, by application
7.5.5.9. South Africa market size and forecast, by end user
7.5.5.10. Rest of LAMEA market size and forecast, by product
7.5.5.11. Rest of LAMEA market size and forecast, by application
7.5.5.12. Rest of LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. ABBVIE INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segment
8.1.4. Product portfolio
8.1.5. Business performance
8.2. BAXTER INTERNATIONAL INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.3. Fresenius SE & Co. KGaA
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Halocarbon Products Corporation.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.5. Hikma Pharmaceuticals PLC
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Jiangsu Hengrui Medicine Co. , Ltd.
8.6.1. Company overview
8.6.2. Operating business segments
8.6.3. Product portfolio
8.7. Lunan Pharmaceutical Group Co. Ltd.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. Novartis AG.
8.8.1. Company overview
8.8.2. Operating business segments
8.8.3. Product portfolio
8.8.4. Business performance
8.8.5. Key strategic moves and developments
8.9. Piramal Enterprises Ltd.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. Troikaa Pharmaceuticals, Ltd.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio

Executive Summary

According to this report titled, 'Malaria Diagnostics Market by Product Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global malaria diagnostics market size was valued at $728,870 thous and in 2018, and is expected to reach $1,085,106thous and by 2026, registering a CAGR of 5.1% from 2019 to 2026.

Malaria is a serious infectious disease, which can be lethal for the host if left untreated. Furthermore, it is transmitted through the bite of infected female Anopheles mosquito. The bite leads to spreading of Plasmodium parasites into the blood, which, in, turn spread to liver cells where they multiply at a fast rate to invade red blood cells. These parasites further grow and mature in red blood cells to form merozoites. These merozoites are responsible for rupturing of red blood cells to invade other red blood cells. This leads to fever, tiredness, vomiting, headaches, impaired consciousness, multiple convulsions, and abnormal bleeding. Hence, tests and procedures to identify the disease are necessary and are known as malaria diagnostics. There are different types of malaria diagnostics such as rapid diagnostic tests, microscopy, and molecular diagnostic tests.

The major factor that contributes to the growth of malaria diagnostics market include rise in The prevalence of malaria in developing countries. Furthermore, rise in awareness initiatives by governments and surge in research for new malaria diagnostics are the factors that boost the growth of the market. However, lack of awareness about healthcare in developing countries is the major factor that restricts growth of the malaria diagnostics market. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities during the forecast period.

The malaria diagnostics market is studied on the basis of product type, end user, and region to provide a detailed assessment of the market. On the basis of product type, it is segmented into rapid diagnostic tests, microscopy, and molecular diagnostic tests. By end user, it is bifurcated into hospital, clinics, and diagnostic centers. Region wise, it is analyzed across North America (the U.S., and Canada, and Mexico), Europe (Germany, the UK, and rest of Europe), Asia-Pacific (China, India, and rest of Asia-Pacific), and LAMEA (Africa and rest of LAMEA).

According to product type, rapid diagnostic tests acquired the major share of the malaria diagnostics market in 2018, owing to benefits associated with the use of RDTs in the diagnosis of malaria. For instance, RDTs are inexpensive, simple to operate and read, highly sensitive & specific, stable at high temperatures, and provide results in shorter period of time. Therefore, contribute to the growth of malaria diagnostic tests market. Furthermore, the molecular diagnostic tests segment is expected to grow at the fastest pace during the forecast period, owing to high specificity associated with the use of the test, which can lead to better treatment outcomes. In addition, rise in awareness among people regarding early diagnosis of malaria for better treatment supplements the growing demand for malaria diagnostic tests.

By end user, the clinics segment acquired the major share of the malaria diagnostics market, owing to surge in number of clinics worldwide. In addition, diagnostic centers are expected to exhibit the fastest growth rate during the forecast period due to surge in awareness related to early diagnosis of malaria infection for better treatment.

By region, LAMEA accounted for the major malaria diagnostics market share in 2018, and is expected to continue this trend, owing to rapid surge in The prevalence of malaria in the region. Moreover, widespread of the malaria vector, Anopheles gambiae, which is difficult to control, in the region is another major factor that leads to surge in cases of malaria. Furthermore, majority of malarial infections in the region are caused by the most lethal type of malarial parasite called as Plasmodium falciparum. Therefore, there is a need for early diagnosis of malaria infection in this region, which boosts the growth of the market. In addition, malaria infection is endemic to some parts of Africa, which leads to the growth of the market in the region. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period, attributed to the increase in awareness regarding the use of malaria diagnostics for early diagnosis of the infection for better treatment. The constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia, as the constant development leads to surge in awareness related to the use of malaria diagnostics .

According to Onkar Sumant, Manager, Healthcare, “the demand formalaria diagnostics is on the rise, owing to surge in malaria across the globe. Furthermore, rise in awareness initiatives by governments is another major factor that contributes to the growth of this market.”

KEY FINDINGS OF THE STUDY
  • Rapid diagnostic tests segment occupied approximately half the share of the global malaria diagnostics market in 2018.
  • The molecular diagnostic tests segment is anticipated to grow with the highest CAGR throughout the forecast period.
  • The hospitals segment accounted for one-thirds share of the market in 2018.
  • Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

Companies Mentioned

  • AbbVie Inc.
  • Baxter International Inc.
  • Fresenius SE & Co. KGaA.
  • Halocarbon Products Corporation
  • Hikma Pharmaceuticals PLC.
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Lunan Pharmaceutical Group Co. Ltd
  • Novartis AG
  • Piramal Enterprises Ltd
  • Troikaa Pharmaceuticals L

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information